Johnson & Johnson pulls another drug

Johnson & Johnson is pulling its long-standing blood cancer drug Velcade from the Australian market, with all strengths already removed from the PBS.

The 3.5mg strength was discontinued in Australia on 30 June 2025 while the remaining 1mg and 3mg strength will be discontinued on 30 September 2026.

“We are discontinuing Velcade (bortezomib) 1mg and 3mg, effective in Australia 30 September 2026,” a J&J spokesperson said.

To see the whole article please log in.

Tiffany Walker

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here